Researchers have identified in a new study that oral infigratinib, an FGFR1–3 selective tyrosine kinase inhibitor, improves ...

Achondroplasia dwarfism is the most common type of skeletal dysplasia. It’s the cause for 90% of cases of markedly short stature in people. Achondroplasia targets bone growth in the arms and legs.

Abbisko Cayman Limited ( ($HK:2256) ) has shared an announcement. Abbisko Therapeutics announced that the Center for Drug Evaluation of the China ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in people 4 months and over.

Discover top medications for 'treating Achondroplasia'? This page compiles essential information on generic and brand-name drugs specifically used for Achondroplasia treatment.Here, you can ...

Achondroplasia, hypochondroplasia, and thanatophoric dysplasia are syndromes of short-limbed dwarfism caused by activating mutations of fibroblast growth factor receptor-3, which result in ...